Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Other equities analysts also recently issued reports about the company. JPMorgan Chase & Co. reissued a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Finally, Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.67.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $42.05 on Wednesday. The company has a market cap of $2.39 billion, a PE ratio of -6.65 and a beta of 0.78. The stock has a fifty day moving average price of $38.72 and a 200 day moving average price of $30.98. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $49.06.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The business’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.47) earnings per share. Analysts anticipate that Agios Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the transaction, the director now owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is owned by corporate insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AGIO. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $41,000. China Universal Asset Management Co. Ltd. increased its holdings in Agios Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 5,040 shares in the last quarter. NEOS Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $210,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Agios Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 942 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in Agios Pharmaceuticals by 31.8% during the 4th quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 2,900 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.